Nasal Monoclonal Antibody Suppresses Inflammatory Response in COVID-19

In a new study, a Brigham team determined how nasal foralumab modulates inflammation and describes a potential novel avenue for treating not just COVID-19 but also autoimmune diseases.
Read More...